Diagnostic Accuracy of the MADx Multi Array Xplorer (MAX 45k) Automated Laboratory System and the MADx Allergy Explorer Version 2 (ALEX²) - IgE Multiplex Test for the Diagnosis of Pre-defined Groups of Specific High-priority Allergens
Launched by MACROARRAY DIAGNOSTICS GMBH · Jun 15, 2020
Trial Information
Current as of May 22, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Male and female subjects with suspicion of allergy
- • Written consent of the participant (and/or his/her parent or legal representative) after being informed
- Exclusion Criteria:
- • Oral treatment with corticosteroids (\>5mg/day)
- • Treatment with antihistamines (histamine (H1) receptor blockers)
- • Hematological disease (coagulation disorders, anemia)
About Macroarray Diagnostics Gmbh
MacroArray Diagnostics GmbH is a leading biotechnology company specializing in the development of innovative diagnostic solutions for personalized medicine. Focused on advancing the field of molecular diagnostics, the company utilizes cutting-edge microarray technology to enhance the detection and characterization of various diseases, including infectious diseases and cancer. With a commitment to improving patient outcomes through precise and efficient diagnostic tools, MacroArray Diagnostics collaborates with healthcare professionals and research institutions to bring transformative products to market. Their expertise in biomarker discovery and assay development positions them at the forefront of the evolving landscape of diagnostic healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Graz, , Austria
Vienna, , Austria
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials